EV/EBITDA Multiple: Sagimet (SGMT)

Corporate company logo of sagimet.com (SGMT)

The share price retrospective for Sagimet Biosciences (SGMT) demonstrates an EV/EBITDA ratio of 0.00. The stability of clinical trials is ensured by duplicating chemical raw material procurement channels. The business focuses on developing denifanstat, an oral agent designed to combat liver pathologies and oncology. High growth potential is embedded in the patent protection of the formulas, which, if successful, would allow the company to achieve global leadership with minimal production costs.

SGMT (Sagimet Biosciences, Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/17/2026

Sagimet Biosciences, Inc. (SGMT) - metric breakdowns and financial figures

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Initial company analysis:SGMT (Sagimet Biosciences)
Product sample of Sagimet Biosciences Inc.

EV/EBITDA determines the objective value of a business by comparing total enterprise value with operating profit before interest, taxes, depreciation, and amortization. By analyzing fluctuations in the EV/EBITDA multiple, an investor can see the market valuation of assets relative to their ability to generate cash flow. This metric eliminates the impact of debt load, revealing the real efficiency of capital management. For Sagimet Biosciences (SGMT), this is critical, as multi-year investments in clinical trials and patent protection create high business value despite deferred profits.

Who Sagimet Biosciences competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ascendispharma.com ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics Corp - EV/EBITDA Multiple|Company Value to EBITDA Rhythm Pharmaceuticals Inc|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Pharmaceuticals|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (Soleno Therapeutics Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization amicusrx.com FOLD|89bio Pharma (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Corp|Enterprise Value to EBITDA Ratio MBX Corp (MBX)|EV/EBITDA Multiple ALT|Enterprise Value to EBITDA Ratio Aardvark Therapeutics Inc AARD|EV/EBITDA Multiple BIOA (BioAge)|Biomea Fusion - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|QNCX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GUTS (Fractyl)|VTVT (vTv Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|Agape ATP Corp. (ATPC) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pluri-biotech.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SYBX|EV/EBITDA Multiple LPCN|Matinas BioPharma Holdings - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SPRB (sprucebiosciences.com)|Enterprise Value to Operating Income Before Depreciation Ratio GLTO (galecto.com)|CTCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LUMO|organovo.com (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Radius Health - Business Value to Operating Income Before Depreciation